Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
52.56 USD | +1.70% | +1.23% | -16.29% |
04-24 | Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating | MT |
04-23 | Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.29% | 11.6B | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-14.82% | 15.36B | |
-8.82% | 11.95B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B | |
+0.95% | 7.72B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Incyte : Says FDA Extends Supplemental New Drug Application Review Period for Ruxolitinib